What is a patent cliff and why does it matter for pharmaceutical companies?

A patent cliff occurs when a pharmaceutical company's blockbuster drug loses patent protection, allowing generic competitors to enter the market. This typically causes a sharp decline in revenue from that drug. It matters because many pharma companies rely heavily on a few major products, so losing exclusivity can significantly impact their financial performance and stock price.

How did AbbVie successfully navigate its patent cliff with Humira?

AbbVie successfully replaced declining Humira revenues by launching new blockbuster drugs, particularly Skyrizi and Rinvoq for immunology treatments. These new products generated surging sales that more than compensated for Humira's revenue loss to generic competition, allowing AbbVie to actually raise its profit forecast.

What makes a pharmaceutical company resilient against patent cliffs?

Resilient pharmaceutical companies typically have robust research and development pipelines with multiple promising drugs in various stages of development. They invest heavily in discovering, testing, and commercialising next-generation therapies that can replace revenues from aging products. Strong financial resources and proven track records in drug development also contribute to resilience.

What does 'projected sales' and 'projected profit' mean for pharmaceutical stocks?

Projected sales refers to analysts' estimates of how much revenue a pharmaceutical company is expected to generate in future periods, often based on anticipated drug launches and market performance. Projected profit represents expected earnings after expenses. These projections are particularly important for pharma companies as they help investors assess the potential success of new drug pipelines.

Why might this be a good time to invest in pharmaceutical companies?

AbbVie's successful transition demonstrates that well-managed pharmaceutical companies can not only survive patent cliffs but actually grow stronger. This success story may increase investor confidence in the entire sector's ability to navigate these challenges, potentially creating opportunities in companies with strong pipelines and proven development capabilities.

17 handpicked stocks

Beyond The Patent Cliff: Pharma's New Growth Engines

AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.

Han Tan | Market Analyst

Updated 2 days ago | Published at अगस्त 1